MRK vs DVA
By Alex · Tickerpine
Merck & Co., Inc. vs DaVita Inc., side by side — the numbers that matter, in plain English. No “winner” hype; you decide.
| Metric | MRK | DVA |
|---|---|---|
| Price | $128.66 | $217.04 |
| Market cap | $317.77B | $13.93B |
| P/E ratio | 36.2 | 20.9 |
| ROE | 18.94% | 80.98% |
| Profit margin | 13.59% | 5.65% |
| Revenue growth | 4.90% | 6.00% |
| Dividend yield | 2.64% | — |
| Beta | 0.22 | 0.91 |
Green = the more favorable figure for that metric (lower P/E, higher ROE, margin, growth and yield). Not a recommendation.
MRK vs DVA in plain English
- MRK is the bigger company — about 22.8× the market cap of DVA.
- DVA is cheaper on earnings (P/E 20.9 vs 36.2).
- DVA earns a higher return on equity (81% vs 19%).
- DVA is growing revenue faster (6% vs 5%).
- MRK pays a dividend (2.64%) while the other effectively doesn't.
How would $1,000 have done in each?
MRK return calculator
See what $1,000 in Merck & Co., Inc. would be worth today.
DVA return calculator
See what $1,000 in DaVita Inc. would be worth today.
Figures from public market data, may be delayed. Comparison is informational only — not investment advice.